Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137657
Status:
COMPLETED
Last Update Posted:
2005-12-13
First Post:
2005-08-29
Brief Title:
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
Sponsor:
Centers for Disease Control and Prevention
Organization:
Centers for Disease Control and Prevention
Study Overview
Official Title:
An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum Streptococcus Pneumoniae and Escherichia Coli
Status:
COMPLETED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole trimethoprim sulfamethoxazole CTX prophylaxis Because of the demonstrated beneficial effect high tolerability and low cost of CTX the United Nations Programme on HIVAIDS UNAIDS recommends that HIV-infected persons with symptomatic HIV or depressed CD4 counts receive daily CTX The effect of this recommendation on subsequent development of antimicrobial resistance to antifolates among important pathogens needs to be evaluated The investigators measured the change in the prevalence of markers of antifolate resistance among P falciparum and the change in the prevalence of CTX resistance among S pneumoniae and E coli in HIV-infected individuals receiving CTX daily prophylaxis In addition the investigators measured the change in the prevalence of naso-pharyngeal or oro-pharyngeal carriage of CTX resistant S pneumoniae among children living in households where an HIV-infected adult was receiving CTX daily prophylaxis
Detailed Description:
We conducted this study in Kisumu Kenya where HIV prevalence is high and malaria is highly endemic HIV infected and uninfected adults were assigned to receive daily CTX if CD4 cell count was 350 or daily multivitamin if CD4 cell count was 350 or if the client was HIV negative All clients were then followed for a total of 6 months At specified scheduled and sick visits clients received a physical exam blood smears nasopharyngeal swabs and stool samples or rectal swabs Samples collected at baseline and during follow-up were used to measure the change in CTX resistance among P falciparum parasites pneumococcus isolates and commensal E coli
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SSC664 | None | None | None |
| UR6CCU018970-02-2 | None | None | None |